Skip to main content

Alfa Cognition is an observational and prospective study that analyses the relationship between the subjective perception of cognitive decline and the presence, evolution or risk of cognitive impairment clinically objective. It also analyses the relationship of these parameters with the brain changes associated with Alzheimer's disease ranging from the absence of deterioration to the manifestation of dementia.

200 people over 45 years of age are expected to participate in the study with mild cognitive impairment, mild dementia or no objectionable memory alterations, but who perceive a subjective cognitive decline. Participants come from the Alfa Study or databases of people interested in participating in research studies related to Alzheimer's disease.

Participation in the study involves the carrying out of neurological tests, of neuroimaging, cognitive tests and life habits, and an extraction of blood in order to rule out any condition that could cause cognitive impairment.

Alfa Cognition has three main objectives. First, study the association between the presence of perception of subjective decline in cognitively healthy people and the risk of progressive cognitive impairment. Second, analyze the evolution of the subjective perception of cognitive impairment of the participants and their associates throughout the different phases of Alzheimer's disease. Finally, investigate the relationship between subjective perception of cognitive decline and parameters such as cognitive performance, the presence of brain structural changes determined by magnetic resonance imaging and the presence of alterations in biomarkers of the disease.

 

Principal Investigator of Alfa Cognition

José Luis Molinuevo, scientific director of the Alzheimer's Prevention Program. 

Molinuevo is co-author of more than 280 scientific articles with more than 10,000 citations in prestigious journals, and a 53 index. In addition, he participates in networks related to the standardization of procedures and clinical criteria of Alzheimer’s disease, such as the Alzheimer Biomarker Standarization Initiative, the International Working Group, the National Institute on Aging and Alzheimer's Association (NIA-AA) Research framework, the CSF Appropriate Use Criteria Workgroup, the Standardization of CSF Preanalytics Working Group and the Subjective Cognitive Decline Initiative (SCD-I) Working Group.

Alfa Cognition
Study directed at people with subjective cognitive decline